{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:20:27Z","timestamp":1778901627704,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020908","name":"Pfizer France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020908","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transthyretin amyloidosis (ATTR) is a severe and rare disease characterized by the progressive deposition of misfolded transthyretin proteins, causing irreversible organ damage. Transthyretin amyloidosis can present as a hereditary ATTR or acquired wild-type ATTR form. Genetic testing is critical for determining a hereditary predisposition and subsequently initiating appropriate family screening. In France, strict regulations govern genetic testing that aim to protect patients and their families affected by hereditary diseases such as ATTR. However, challenges persist in establishing an effective genetic testing pathway. A multidisciplinary group of French experts convened to discuss the challenges associated with an ATTR genetic diagnosis and to propose improvement strategies. Key challenges include the lack of pathway standardization, communication gaps between healthcare professionals (HCPs) and patients, and difficulties in complying with regulatory requirements. Concerns about patient data safety and outsourced testing quality further complicate matters. Proposed strategies included the development of stakeholder mapping tools for HCPs and patients, educational programs to improve literacy on genetic testing regulations, increase disease awareness among medical geneticists and genetic counselors, and strengthening HCP-patient communication through educational materials. These initiatives aim to streamline the genetic testing pathway, enhance compliance with regulations, and ultimately provide optimal support for patients and families with ATTR.<\/jats:p>","DOI":"10.1186\/s13023-024-03370-z","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T06:54:34Z","timestamp":1730271274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improving genetic testing pathways for transthyretin amyloidosis in France: challenges and strategies"],"prefix":"10.1186","volume":"19","author":[{"given":"B\u00e9r\u00e9nice","family":"Hebrard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Lise","family":"Babonneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Charron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Consolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Dauriat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Dupin-Deguine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Fargeaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Farrugia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Ga\u00eblle","family":"Giguet-Valard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Guijarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyn","family":"Inamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Jeanneteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Micha\u00ebl","family":"Mazzella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire-C\u00e9cile","family":"Michon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Millat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Mouquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Oghina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Pereon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vianney","family":"Poinsignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Pompougnac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Proukhnitzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Sturtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Trosdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Auguste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Canali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Combes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"Funalot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-3848","authenticated-orcid":false,"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"3370_CR1","doi-asserted-by":"publisher","first-page":"101759","DOI":"10.1016\/j.jaccas.2023.101759","volume":"10","author":"Y Brailovsky","year":"2023","unstructured":"Brailovsky Y, Rajapreyar I, Alvarez R. TTR Amyloidosis: Current State of Affairs and Promise for the Future. JACC Case Rep. 2023;10:101759.","journal-title":"JACC Case Rep"},{"issue":"3","key":"3370_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/HCO.0000000000000841","volume":"36","author":"R Alreshq","year":"2021","unstructured":"Alreshq R, Ruberg FL. Clinical approach to genetic testing in amyloid cardiomyopathy: from mechanism to effective therapies. Curr Opin Cardiol. 2021;36(3):309\u201317.","journal-title":"Curr Opin Cardiol"},{"issue":"Suppl 2","key":"3370_CR3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10072-020-04889-2","volume":"43","author":"F Manganelli","year":"2022","unstructured":"Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D. Hereditary transthyretin amyloidosis overview. Neurol Sci. 2022;43(Suppl 2):595\u2013604.","journal-title":"Neurol Sci"},{"key":"3370_CR4","unstructured":"Rowczenio D, Wechalekar A. Mutations in Hereditary Amyloidosis 2015. Available from: http:\/\/amyloidosismutations.com\/mut-attr.php."},{"key":"3370_CR5","unstructured":"Yoshiki S. Hereditary Transthyretin Amyloidosis\u2014updated in 2021. In: Adam MP, et. al., editors. Gene Reviews. University of Washington, Seattle, 2001."},{"issue":"1","key":"3370_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13023-023-02933-w","volume":"18","author":"T Damy","year":"2023","unstructured":"Damy T, Bourel G, Slama M, Algalarrondo V, Lairez O, Fournier P, Costa J, Pelcot F, Farrugia A, Zaleski ID, Lilliu H, Rault C, Bartoli M, Fievez S, Granghaud A, Rudant J, Coste A, Cosson CN, Squara PA, Narbeburu M, De Neuville B, Charron P. Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases. Orphanet J Rare Dis. 2023;18(1):345.","journal-title":"Orphanet J Rare Dis"},{"issue":"23","key":"3370_CR7","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","volume":"37","author":"T Damy","year":"2016","unstructured":"Damy T, Costes B, Hag\u00e8ge AA, Donal E, Eicher JC, Slama M, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37(23):1826\u201334.","journal-title":"Eur Heart J"},{"issue":"4","key":"3370_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23(4):512\u201326.","journal-title":"Eur J Heart Fail"},{"key":"3370_CR9","unstructured":"HAS. Protocole National de Diagnostic et de Soins (PNDS): Neuropathie amylo\u00efde familiale. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-12\/pnds_amyloses_cardiaques_v20_version_finale_31082021.pdf."},{"key":"3370_CR10","unstructured":"HAS. Protocole National de Diagnostic et de Soins (PNDS): Amyloses Cardiaques 2021. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2017-05\/dir2\/pnds_-_neuropathies_amyloides_familiales.pdf."},{"key":"3370_CR11","unstructured":"HAS. R\u00e8gles de bonnes pratiques en g\u00e9n\u00e9tique constitutionnelle \u00e0 des fins m\u00e9dicales"},{"key":"3370_CR12","unstructured":"Hors Diagnostic Pr\u00e9natal 2010. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2013-02\/regles_de_bonne_pratique_en_genetique_constitutionnelle_a_des_fins_medicales.pdf."},{"key":"3370_CR13","unstructured":"L\u00e9gifrance. Code de la sant\u00e9 publique 2021. Available from: https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000043896220?init=true&page=1&query=Article+L1132-1+-+Code+de+la+sant%C3%A9+publique&searchField=ALL&tab_selection=all."},{"issue":"4","key":"3370_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1300\/J010v06n04_02","volume":"6","author":"JO Weiss","year":"1981","unstructured":"Weiss JO. Psychosocial stress in genetic disorders: a guide for social workers. Soc Work Health Care. 1981;6(4):17\u201331.","journal-title":"Soc Work Health Care"},{"key":"3370_CR15","unstructured":"GDPR. Chapter 5: Transfers of personal data to third countries or international organisations. Available from: https:\/\/gdpr-info.eu\/chapter-5\/."},{"issue":"10","key":"3370_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.acvd.2023.07.003","volume":"116","author":"T Damy","year":"2023","unstructured":"Damy T, Zaroui A, de Tournemire M, Kharoubi M, Gounot R, Galat A, et al. Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France. Arch Cardiovasc Dis. 2023;116(10):433\u201346.","journal-title":"Arch Cardiovasc Dis"},{"issue":"5","key":"3370_CR17","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/jcm9051365","volume":"9","author":"C Bordet","year":"2020","unstructured":"Bordet C, Brice S, Maupain C, Gandjbakhch E, Isidor B, Palmyre A, et al. Psychosocial impact of predictive genetic testing in hereditary heart diseases: the PREDICT study. J Clin Med. 2020;9(5):1365.","journal-title":"J Clin Med"},{"key":"3370_CR18","unstructured":"L\u00e9gifrance. Arr\u00eat\u00e9 du 27 mai 2013 d\u00e9finissant les r\u00e8gles de bonnes pratiques applicables \u00e0 l'examen des caract\u00e9ristiques g\u00e9n\u00e9tiques d'une personne \u00e0 des fins m\u00e9dicales 2024. Available from: https:\/\/www.legifrance.gouv.fr\/loda\/id\/JORFTEXT000027513617."},{"key":"3370_CR19","unstructured":"L\u00e9gifrance. Code civil 2023.Available from: https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000043895858#:~:text=Version%20en%20vigueur%20depuis%20le%2021%20mai%202023,-Modifi%C3%A9%20par%20LOI&text=I.,la%20r%C3%A9alisation%20de%20l%27examen."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03370-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03370-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03370-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:38:58Z","timestamp":1730295538000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03370-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3370"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03370-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BD, BF, BH, DG, EC, ES, FM, JPo, SO, TD and YP have received honoraria from Pfizer related to this work. BD has received honoraria from Pfizer. ES has received honoraria from Alnylam and Pfizer. FM has received honoraria from BMS and Pfizer. PC has received honoraria from Amicus, BMS, Owkin, Pfizer and Sanofi. SO has received honoraria from Pfizer. TD has received honoraria from Alexion, Alnylam, Akcea, Bridge Bio, Ionis, Neurimmune, Novo Nordisk and Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"403"}}